These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 20571067

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 3. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Fribley A, Zeng Q, Wang CY.
    Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C, Li R, Grandis JR, Johnson DE.
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE.
    Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
    [Abstract] [Full Text] [Related]

  • 7. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ.
    Cancer Res; 2006 Apr 01; 66(7):3773-81. PubMed ID: 16585204
    [Abstract] [Full Text] [Related]

  • 8. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF.
    Oral Oncol; 2012 Jul 01; 48(7):585-93. PubMed ID: 22342571
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF, Lam BH, Ho DN, Tsao SW, Chiang AK.
    Mol Cancer Ther; 2013 May 01; 12(5):747-58. PubMed ID: 23475956
    [Abstract] [Full Text] [Related]

  • 10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 11. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
    Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM.
    Clin Cancer Res; 2005 May 01; 11(9):3558-66. PubMed ID: 15867260
    [Abstract] [Full Text] [Related]

  • 12. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
    Sato A, Asano T, Isono M, Ito K, Asano T.
    BMC Urol; 2014 Aug 30; 14():71. PubMed ID: 25176354
    [Abstract] [Full Text] [Related]

  • 13. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J.
    PLoS One; 2012 Aug 30; 7(12):e52576. PubMed ID: 23285100
    [Abstract] [Full Text] [Related]

  • 14. Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
    Kiliccioglu I, Konac E, Varol N, Gurocak S, Yucel Bilen C.
    Genet Mol Res; 2014 May 09; 13(2):3721-31. PubMed ID: 24854658
    [Abstract] [Full Text] [Related]

  • 15. Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
    Fang Y, Hu Y, Wu P, Wang B, Tian Y, Xia X, Zhang Q, Chen T, Jiang X, Ma Q, Xu G, Wang S, Zhou J, Ma D, Meng L.
    Cancer Invest; 2011 May 09; 29(4):247-52. PubMed ID: 21345073
    [Abstract] [Full Text] [Related]

  • 16. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
    Yang J, McEachern D, Li W, Davis MA, Li H, Morgan MA, Bai L, Sebolt JT, Sun H, Lawrence TS, Wang S, Sun Y.
    Mol Cancer Ther; 2011 Apr 09; 10(4):658-69. PubMed ID: 21282353
    [Abstract] [Full Text] [Related]

  • 17. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
    Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN.
    Clin Cancer Res; 2010 Oct 01; 16(19):4742-54. PubMed ID: 20647473
    [Abstract] [Full Text] [Related]

  • 18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 01; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 19. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Zang Y, Kirk CJ, Johnson DE.
    Cancer Biol Ther; 2014 Sep 01; 15(9):1142-52. PubMed ID: 24915039
    [Abstract] [Full Text] [Related]

  • 20. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM.
    Clin Cancer Res; 2009 May 15; 15(10):3354-65. PubMed ID: 19417023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.